by
Gus Iversen, Editor in Chief | July 10, 2026
GE HealthCare and Mayo Clinic have launched a research collaboration to study whether imaging and biomarker data can help personalize radioligand therapy (RLT) for patients with advanced prostate cancer.
The study, known as MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial), builds on the Strategic Radiology Research Alliance established by the two organizations in 2023. Researchers will examine whether treatment duration can be tailored based on an individual patient's response rather than relying on a standard number of therapy cycles.
RLT is a theranostics approach that pairs diagnostic imaging with targeted radioactive therapies. The MI-BET study will investigate whether serial imaging, clinical outcomes and blood-based biomarkers can identify patients whose treatment could be paused based on disease response over time.
Ad Statistics
Times Displayed: 22349
Times Visited: 59 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
The Rochester, Minnesota-based Mayo Clinic will use GE HealthCare's StarGuide SPECT/CT system together with MIM Software's MIM LesionID Pro to monitor tumor response during treatment. Researchers also plan to evaluate whether combined imaging and biomarker data can contribute to the development of predictive markers that could help clinicians anticipate treatment response earlier in the course of therapy.
"Personalizing therapy is both a scientific pursuit and an opportunity to expand patient access," said Geoffrey Johnson, M.D., Ph.D., chair of the Radiopharmaceutical Trial Team at Mayo Clinic Comprehensive Cancer Center. "Theranostics, and studies such as MI-BET, give us an important opportunity to rethink how and when we treat cancer."
According to the organizations, the study will include outreach efforts intended to support broader patient participation, including collaboration with community and advocacy groups and the use of telemedicine to reduce barriers to enrollment.
Research will be conducted at Mayo Clinic's Rochester campus. The site will also be the first in the United States to evaluate GE HealthCare's StarGuide GX SPECT/CT system in a research setting. The company said the system, which has CE marking but is not cleared by the FDA, will be assessed for its potential to shorten scan times and improve tumor assessment.
